Cyclacel Pharmaceuticals to Present Sapacitabine Phase I data at US American Society of Hematology Conference
Cyclacel Pharmaceuticals Announces Sapacitabine Poster Presentation at Upcoming American Society of Hematology Meeting
BERKELEY HEIGHTS, NJ December 6, 2007 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today updated Phase I clinical trial results of sapacitabine for the treatment of advanced leukemias or myelodysplastic syndromes will be presented at the 2007 American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, GA, on Saturday, December 8, 2007.
The poster details are as follows:
Title: Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).
Date/Time: Saturday, December 8, 2007, 9:00 AM - 7:30 PM EST
Session: Acute Myeloid Leukemia: Biology and Pathophysiology I
Poster board: #38-I
Abstract: 884
The abstract is currently available online at www.abstracts2view.com/hem07.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(r) Cream for radiation dermatitis, Numoisyn(r) Liquid and Numoisyn(r) Lozenges for xerostomia. Three Cyclacel drugs are in clinical development. Sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, is in Phase II for the treatment of cutaneous T-cell lymphoma (CTCL) and in Phase I in patients with hematologic malignancies. Seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, is in two randomized Phase II studies for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is in Phase I development in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in oncology, hematology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.
Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases <http://www.cyclacel.com/cyc/investors/news/pressreleases/> for additional information. Note: The Cyclacel logo and Cyclacel(r) are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn(r) and Xclair(r) are trademarks of Sinclair Pharma plc.
European media and IR contact for Cyclacel Pharmaceuticals:
Sue Charles and Justine Lamond
College Hill
Ph: +44 (0)20 7866 7857
Forward-Looking Statements & Risk Factors
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2006, as supplemented by the interim quarterly reports, filed with the SEC.
Justine Lamond
Please consider the environment before printing this email
Northbank Communications is now College Hill Life Sciences. From 26 November our London address is...
CollegeHill
Click here for our location <http://www.collegehill.com/lifesciences/contact.htm>
The Registry Royal Mint Court London EC3N 4QN
T +44(0)20 7457 2020 F +44(0)20 7866 7900 www.collegehill.com/lifesciences <http://www.collegehill.com/lifesciences>
This email, its content and any files transmitted with it are confidential and are intended only for the addressee. If you are not the addressee, you may not print, copy, use or rely on the contents, attachments or information in any way except with the express written permission of the sender. If this email has been sent to you in error please destroy it and contact the sender. This email has been prepared using information believed by the author to be reliable and accurate, but College Hill makes no warranty as to its accuracy or completeness. In particular, College Hill does not accept changes made to this email after it was sent.
Company Name: College Hill Associates Ltd, Company Number: 1036926 Registered Address: The Registry, Royal Mint Court, London EC3N 4QN UK
Posted: December 2007
